Blog Archive

Search This Blog

Monday, July 31, 2017

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands

Condition:   Advanced Solid Tumors With Overexpression of Epidermal Growth Factor Receptor (EGFR) or EGFR Ligands
Intervention:   Drug: ABBV-321
Sponsor:   AbbVie
Not yet recruiting - verified July 2017

from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2vlzKbo

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Blog Archive

Pages

   International Journal of Environmental Research and Public Health IJERPH, Vol. 17, Pages 6976: Overcoming Barriers to Agriculture Green T...